Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AIM ImmunoTech (AIM) Payables (2018 - 2025)

Historic Payables for ImmunoTech (AIM) over the last 11 years, with Q3 2025 value amounting to $3.1 million.

  • ImmunoTech's Payables fell 6463.81% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 6463.81%. This contributed to the annual value of $8.7 million for FY2024, which is 3487.51% up from last year.
  • Latest data reveals that ImmunoTech reported Payables of $3.1 million as of Q3 2025, which was down 6463.81% from $9.6 million recorded in Q2 2025.
  • ImmunoTech's Payables' 5-year high stood at $9.6 million during Q2 2025, with a 5-year trough of $2.2 million in Q2 2023.
  • Over the past 3 years, ImmunoTech's median Payables value was $8.0 million (recorded in 2024), while the average stood at $6.7 million.
  • Per our database at Business Quant, ImmunoTech's Payables skyrocketed by 26304.04% in 2024 and then tumbled by 6463.81% in 2025.
  • Quarter analysis of 3 years shows ImmunoTech's Payables stood at $6.4 million in 2023, then surged by 34.88% to $8.7 million in 2024, then crashed by 63.96% to $3.1 million in 2025.
  • Its Payables was $3.1 million in Q3 2025, compared to $9.6 million in Q2 2025 and $8.9 million in Q1 2025.